ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer

Published:2020-01-17 Issue:9 Volume:26 Page:2244-2256
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Okura Naoko,Nishioka Naoya,Yamada Tadaaki,Taniguchi Hirokazu,Tanimura Keiko,Katayama Yuki,Yoshimura Akihiro^ORCID,Watanabe Satoshi^ORCID,Kikuchi Toshiaki^ORCID,Shiotsu Shinsuke,Kitazaki Takeshi,Nishiyama Akihiro,Iwasaku Masahiro,Kaneko Yoshiko,Uchino Junji^ORCID,Uehara Hisanori,Horinaka Mano,Sakai Toshiyuki,Tanaka Kohei,Kozaki Ryohei,Yano Seiji,Takayama Koichi^ORCID

Funder

Japan Society for the Promotion of Science

Takeda Science Foundation

Cancer Research institute of Kanazawa University

Japan Lung Cancer Society

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions;Translational Oncology;2024-11

2. Transglutaminase 2 function in glioblastoma tumor efferocytosis;2024-08-30

3. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14

4. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer;Cancer Letters;2024-08

5. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib;Cell Reports Medicine;2024-08